Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer/Ligand’s Osteoporosis Drug Fablyn Gets Advisory Committee Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Lasofoxifene beats out Wyeth’s Viviant for first advisory committee review of the competing next-generation SERMs.

You may also be interested in...

Wyeth’s Viviant “Approvable” For Osteoporosis

Analysis sought for treatment indication is similar to what FDA requested for prevention setting.

Pfizer Files Lasofoxifene NDA For Treatment Of Osteoporosis

Selective estrogen receptor modulator now is called Fablyn rather than Oporia, a name under which it received two “not approvable” letters.

Wyeth’s Viviant “Approvable” For Prevention Of Postmenopausal Osteoporosis

Firm continues to plan an additional submission this year for an osteoporosis treatment claim.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts